Pay in 4 interest-free payments of $5.16 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
Phase 1 registry record NCT02637284 (sponsor PharmaCotherapia) studied oral safety and pharmacokinetics
Susceptibility of acute myeloid leukemia cells to ferroptosis and evasion strategies
Yes for any in vitro biological assay where reconstituted peptide is added to cell cultures, include matched Bacteriostatic Water vehicle controls at the same final benzyl alcohol concentration as the highest peptide treatment to confirm absence of benzyl alcohol-mediated effects on assay endpoints
The current combined third-party report for lot HEL-4339222 provides component-specific results: BPC-157 labeled 10 mg, tested content 9.85 mg, purity 99.36%
US$ 26.01
US$ 27.45
US$ 27.74
US$ 24.59
